Ascentage Pharma (AAPG) director details option and RSU holdings

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL director David Sidransky has reported his initial equity holdings. He holds options linked to 56,550 Ordinary Shares with an exercise price of $8.14 per share, expiring on November 26, 2035. These stock options vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029.

He also holds 66,550 restricted stock units, each representing a right to receive one Ordinary Share upon vesting. These RSUs vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029 and have no expiration date. The filing does not show any open-market buying or selling activity, only existing awards.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SIDRANSKY DAVID

(Last) (First) (Middle)

700 KING FARM BLVD

STE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	11/26/2035	Ordinary Shares	56,550	$8.14(2)	D
Restricted stock units	(3)	(3)	Ordinary Shares	66,550	$0	D

Explanation of Responses:

1. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.

Remarks:

	David Sidransky	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider equity holdings did David Sidransky report at Ascentage Pharma (AAPG)?

David Sidransky reported holding options over 56,550 Ordinary Shares and 66,550 restricted stock units in Ascentage Pharma. These positions represent equity-based compensation awards rather than open-market share purchases or sales, with vesting spread across several future years.

What are the key terms of David Sidransky’s stock options in Ascentage Pharma (AAPG)?

Sidransky’s stock options relate to 56,550 Ordinary Shares with an exercise price of $8.14 per share, converted from HKD at grant. The options vest in four equal annual tranches from November 26, 2026 through November 26, 2029 and expire on November 26, 2035.

How do David Sidransky’s Ascentage Pharma (AAPG) RSUs vest?

His 66,550 restricted stock units each convert into one Ordinary Share upon vesting. The RSUs vest in four equal annual installments on November 26, 2026, 2027, 2028 and 2029, providing a multi‑year equity incentive with no stated expiration date.

Does this Ascentage Pharma (AAPG) Form 3 show any insider share purchases or sales?

The Form 3 does not show any open‑market share purchases or sales by David Sidransky. It reports his existing equity awards—stock options and restricted stock units—along with their vesting schedules, exercise price and expiration terms as his initial beneficial ownership disclosure.

What currency is used for David Sidransky’s Ascentage Pharma (AAPG) option exercise price?

The stock option exercise price is originally denominated in Hong Kong dollars, but the reported $8.14 per‑share figure reflects conversion to U.S. dollars using the exchange rate on the grant date, as clarified in the accompanying footnote.

What type of SEC filing is this for Ascentage Pharma (AAPG) and what is its purpose?

This is a Form 3, which is an initial beneficial ownership report for insiders. It discloses David Sidransky’s existing equity awards—options and restricted stock units in Ascentage Pharma—when he became a director, without indicating any new market transactions.